ArticlePloS one2010
Exploring the link between germline and somatic genetic alterations in breast carcinogenesis.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.ACS medicinal chemistry letters · 2024Article
- Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.bioRxiv : the preprint server for biology · 2024Article
- Functional Roles of DYRK2 as a Tumor Regulator.Current issues in molecular biology · 2023Review
- Image-Based Deep Neural Network for Individualizing Radiotherapy Dose Is Transportable Across Health Systems.JCO clinical cancer informatics · 2023Article
- Modulation of EphA7 and pEphA7 Protein Expression: Potential Biomarkers for Early Detection of Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.Cell death & disease · 2021Article
- The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities.Cancers · 2020Review
- Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes.Nature communications · 2020Article
- Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer.International journal of genomics · 2020Article
- Germline Variants Impact Somatic Events during Tumorigenesis.Trends in genetics : TIG · 2019Review
- Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3,554 patients.Oncology letters · 2019Article
- Integrating Germline and Somatic Mutation Information for the Discovery of Biomarkers in Triple-Negative Breast Cancer.International journal of environmental research and public health · 2019Article
- Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.BMC cancer · 2019Article
- Interactions between Germline and Somatic Mutated Genes in Aggressive Prostate Cancer.Prostate cancer · 2019Article
- Tumor suppressive role for kinases phosphorylating p53 in DNA damage-induced apoptosis.Cancer science · 2018Review
- Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.Nature cell biology · 2016Article
- Therapeutic targeting of EPH receptors and their ligands.Nature reviews. Drug discovery · 2014Review
- Eph receptor and ephrin function in breast, gut, and skin epithelia.Cell adhesion & migration · 2014Review
- Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation.The Journal of biological chemistry · 2013Article
- Eph-dependent cell-cell adhesion and segregation in development and cancer.Cellular and molecular life sciences : CMLS · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent genome-wide association studies (GWASs) have identified candidate genes contributing to cancer risk through low-penetrance mutations. Many of these genes were unexpected and, intriguingly, included well-known players in carcinogenesis at the somatic level. To assess the hypothesis of a germline-somatic link in carcinogenesis, we evaluated the distribution of somatic gene labels within the ordered results of a breast cancer risk GWAS. This analysis suggested frequent influence on risk of genetic variation in loci encoding for "driver kinases" (i.e., kinases encoded by genes that showed higher somatic mutation rates than expected by chance and, therefore, whose deregulation may contribute to cancer development and/or progression). Assessment of these predictions using a population-based case-control study in Poland replicated the association for rs3732568 in EPHB1 (odds ratio (OR) = 0.79; 95% confidence interval (CI): 0.63-0.98; P(trend) = 0.031). Analyses by early age at diagnosis and by estrogen receptor α (ERα) tumor status indicated potential associations for rs6852678 in CDKL2 (OR = 0.32, 95% CI: 0.10-1.00; P(recessive) = 0.044) and rs10878640 in DYRK2 (OR = 2.39, 95% CI: 1.32-4.30; P(dominant) = 0.003), and for rs12765929, rs9836340, rs4707795 in BMPR1A, EPHA3 and EPHA7, respectively (ERα tumor status P(interaction)<0.05). The identification of three novel candidates as EPH receptor genes might indicate a link between perturbed compartmentalization of early neoplastic lesions and breast cancer risk and progression. Together, these data may lay the foundations for replication in additional populations and could potentially increase our knowledge of the underlying molecular mechanisms of breast carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.